{"Symbol": "ABEO", "AssetType": "Common Stock", "Name": "Abeona Therapeutics Inc", "Description": "Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.", "CIK": "318306", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "6555 CARNEGIE AVENUE, CLEVELAND, OH, UNITED STATES, 44103", "OfficialSite": "https://www.abeonatherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "271499000", "EBITDA": "-80984000", "PERatio": "4.141", "PEGRatio": "0", "BookValue": "3.268", "DividendPerShare": "None", "DividendYield": "None", "EPS": "1.21", "RevenuePerShareTTM": "0.008", "ProfitMargin": "205.88", "OperatingMarginTTM": "-208.02", "ReturnOnAssetsTTM": "-0.296", "ReturnOnEquityTTM": "0.759", "RevenueTTM": "400000", "GrossProfitTTM": "-29282000", "DilutedEPSTTM": "1.21", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-1", "AnalystTargetPrice": "20.64", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "6", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "4.141", "ForwardPE": "500", "PriceToSalesRatioTTM": "678.75", "PriceToBookRatio": "1.586", "EVToRevenue": "221.22", "EVToEBITDA": "0.985", "Beta": "1.132", "52WeekHigh": "7.54", "52WeekLow": "3.933", "50DayMovingAverage": "5.16", "200DayMovingAverage": "5.69", "SharesOutstanding": "54191000", "SharesFloat": "42603100", "PercentInsiders": "11.079", "PercentInstitutions": "65.678", "DividendDate": "None", "ExDividendDate": "None"}